title: Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor.
abstract: The long plasma half-life of IgG, while allowing for enhanced tumor uptake of tumor-targeted IgG conjugates, also results in increased background activity and normal-tissue toxicity. Therefore, successful therapeutic uses of conjugated antibodies have been limited to the highly sensitive and readily accessible hematopoietic tumors. We report a therapeutic strategy to beneficially alter the pharmacokinetics of IgG antibodies via pharmacological inhibition of the neonatal Fc receptor (FcRn) using high-dose IgG therapy. IgG-treated mice displayed enhanced blood and whole-body clearance of radioactivity, resulting in better tumor-to-blood image contrast and protection of normal tissue from radiation. Tumor uptake and the resultant therapeutic response was unaltered. Furthermore, we demonstrated the use of this approach for imaging of tumors in humans and discuss its potential applications in cancer imaging and therapy. The ability to reduce the serum persistence of conjugated IgG antibodies after their infusion can enhance their therapeutic index, resulting in improved therapeutic and diagnostic efficacy.
authors: Molecular Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
authors: Jaspreet Singh
authors: JS
authors: Jaggi
authors: Jorge A
authors: JA
authors: Carrasquillo
authors: Surya V
authors: SV
authors: Seshan
authors: Pat
authors: P
authors: Zanzonico
authors: Erik
authors: E
authors: Henke
authors: Andrew
authors: A
authors: Nagel
authors: Jazmin
authors: J
authors: Schwartz
authors: Brad
authors: B
authors: Beattie
authors: Barry J
authors: BJ
authors: Kappel
authors: Debjit
authors: D
authors: Chattopadhyay
authors: Jing
authors: J
authors: Xiao
authors: George
authors: G
authors: Sgouros
authors: Steven M
authors: SM
authors: Larson
authors: David A
authors: DA
authors: Scheinberg
mesh_terms: D000186:Actinium / Q000737:chemistry; D000818:Animals; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000378:metabolism*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D007167:Immunotherapy; D007205:Indium Radioisotopes / Q000737:chemistry; D007275:Injections, Intravenous; D007457:Iodine Radioisotopes; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D049268:Positron-Emission Tomography; D011961:Receptors, Fc / Q000378:metabolism*; D013997:Time Factors
chemical_list: D015395:Histocompatibility Antigens Class I; D007074:Immunoglobulin G; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D011961:Receptors, Fc; D000186:Actinium; C100688:Fc receptor, neonatal
references: J Nucl Med. 2004 Jan;45(1):129-37
references: 14734685
references: J Clin Invest. 1995 May;95(5):2397-402
references: 7738203
references: Clin Lab. 2004;50(3-4):133-40
references: 15074465
references: J Clin Invest. 2004 May;113(9):1328-33
references: 15124024
references: Nat Rev Drug Discov. 2004 Jun;3(6):488-99
references: 15173838
references: Allergy. 2004 Oct;59(10):1124; author reply 1124
references: 15355473
references: J Pharm Sci. 2004 Nov;93(11):2645-68
references: 15389672
references: Prog Allergy. 1969;13:1-110
references: 4186070
references: Clin Exp Immunol. 1972 Apr;10(4):599-607
references: 4624553
references: Nature. 1989 Jan 12;337(6203):184-7
references: 2911353
references: J Nucl Med. 2005 Jan;46 Suppl 1:164S-71S
references: 15653665
references: Cancer Res. 2005 Jan 15;65(2):622-31
references: 15695407
references: Cancer Res. 2005 Jun 1;65(11):4888-95
references: 15930310
references: J Am Soc Nephrol. 2005 Sep;16(9):2677-89
references: 15987754
references: Nat Biotechnol. 2005 Oct;23(10):1283-8
references: 16186811
references: Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5084-9
references: 16549777
references: Trends Immunol. 2006 Jul;27(7):343-8
references: 16731041
references: Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):638-42
references: 1530991
references: Int Immunol. 2006 Dec;18(12):1759-69
references: 17077181
references: Eur J Immunol. 1996 Mar;26(3):690-6
references: 8605939
references: Eur J Immunol. 1996 Jul;26(7):1527-31
references: 8766556
references: J Immunol. 1996 Oct 15;157(8):3317-22
references: 8871627
references: Immunology. 1996 Dec;89(4):573-8
references: 9014824
references: J Immunol. 1997 Mar 1;158(5):2211-7
references: 9036967
references: Immunol Res. 1997 Feb;16(1):29-57
references: 9048207
references: Nat Biotechnol. 1997 Jul;15(7):637-40
references: 9219265
references: Int Immunol. 1998 Sep;10(9):1289-98
references: 9786428
references: N Engl J Med. 1999 Jan 21;340(3):227-8
references: 9895405
references: Eur J Immunol. 1999 Sep;29(9):2819-25
references: 10508256
references: J Clin Invest. 1960 Apr;39:565-72
references: 14417400
references: J Nucl Med. 2005 Jan;46 Suppl 1:128S-40S
references: 15653661
references: J Immunol. 2004 Feb 15;172(4):2021-9
references: 14764666
references: Oncogene. 2000 Feb 3;19(5):649-60
references: 10698510
references: Immunology. 2000 Jun;100(2):245-51
references: 10886402
references: Blood. 2001 Nov 15;98(10):3136-42
references: 11698302
references: Int Immunol. 2001 Dec;13(12):1551-9
references: 11717196
references: J Immunol. 2002 Nov 1;169(9):5171-80
references: 12391234
references: Appl Radiat Isot. 2002 Dec;57(6):841-7
references: 12406626
references: J Immunol. 2003 Apr 1;170(7):3528-33
references: 12646614
references: Cancer Biother Radiopharm. 2003 Feb;18(1):35-46
references: 12667307
references: Cancer Res. 2003 Aug 15;63(16):5084-90
references: 12941838
references: J Mol Biol. 2003 Sep 26;332(4):901-13
references: 12972260